Lyme Disease Antibiotic Treatment — Doxycycline, Amoxicillin, Ceftriaxone, and Stage-by-Stage Protocols

Table of Contents

  1. How Antibiotics Kill Borrelia
  2. Doxycycline — The First-Line Choice
  3. Amoxicillin — For Children and Pregnancy
  4. Cefuroxime — The Oral Alternative
  5. IV Ceftriaxone — When Oral Isn't Enough
  6. Stage-by-Stage Treatment Guide
  7. Lyme Arthritis — 28-Day Protocol
  8. Post-Exposure Prophylaxis
  9. The Herxheimer Reaction
  10. What Not to Do — Prolonged Antibiotic Courses
  11. Research Papers
  12. Connections
  13. Featured Videos

How Antibiotics Kill Borrelia

Borrelia burgdorferi is susceptible to several antibiotic classes through distinct mechanisms, and it does not develop significant clinical antibiotic resistance. Understanding the mechanism helps explain why certain antibiotics are preferred for certain situations.

Tetracyclines (doxycycline) work by binding to the 30S ribosomal subunit of bacterial ribosomes, blocking the attachment of aminoacyl-tRNA to the ribosome's A site. This halts protein synthesis without killing the cell directly — tetracyclines are bacteriostatic in mechanism — but the effect is fully sufficient to cure Lyme disease when spirochetes cannot proliferate. Doxycycline penetrates tissues well, achieving therapeutic concentrations in the synovium, CSF (at higher doses), and cardiac tissue.

Beta-lactam antibiotics (amoxicillin, cefuroxime, ceftriaxone) inhibit cell wall synthesis by covalently binding to penicillin-binding proteins (PBPs), enzymes responsible for cross-linking peptidoglycan strands in the bacterial cell wall. Disruption of this cross-linking leads to cell wall instability and bacterial lysis. Although Borrelia has an unusual cell structure — including an outer membrane with lipoproteins but limited peptidoglycan — it remains susceptible to beta-lactam antibiotics, and these drugs are bactericidal against Borrelia in vitro and clinically effective in humans.

Antibiotic-refractory Lyme arthritis — joint inflammation that persists after two adequate antibiotic courses — represents an immune-mediated process, not bacterial resistance. The spirochetes have been cleared, but the immune response (including autoimmune cross-reactivity) continues to drive synovitis. This is why adding more antibiotics does not help, but anti-inflammatory drugs do.

Doxycycline — The First-Line Choice

Doxycycline is the preferred antibiotic for Lyme disease in adults and children over 8 years of age, and for most stages of the disease. Its combination of efficacy, twice-daily dosing convenience, broad tissue penetration, and coverage of common tick co-infections makes it the first choice in current IDSA guidelines.

Dosing: 100 mg orally twice daily, or 200 mg once daily (both approaches have equivalent efficacy). For early localized Lyme (EM rash without systemic features), 10 days is the recommended duration. For early disseminated disease with mild manifestations (early neurological features, mild cardiac involvement without high-degree AV block), 14–21 days. For Lyme arthritis, 28 days. For neurological Lyme not requiring IV therapy (e.g., facial palsy without meningitis), 14–21 days.

Key co-infection advantage: Deer ticks can transmit Anaplasma phagocytophilum and Ehrlichia species alongside Borrelia burgdorferi. Doxycycline covers all three organisms. Amoxicillin and cefuroxime do not, so if co-infection is clinically suspected, doxycycline is strongly preferred even in patients who might otherwise be candidates for amoxicillin.

Common side effects and how to manage them: Photosensitivity is the most practically important side effect — patients must use broad-spectrum sunscreen and limit prolonged direct sun exposure during the course. Gastrointestinal upset (nausea, esophageal irritation) can be minimized by taking doxycycline with a full 8-ounce glass of water and remaining upright for at least 30 minutes after each dose; taking it with a light meal reduces GI symptoms without significantly impairing absorption. Esophageal ulceration from pill lodging is a serious but preventable complication — never take doxycycline at bedtime without a full glass of water.

Contraindications: Doxycycline is contraindicated during pregnancy (risk of fetal bone and tooth abnormalities) and in children under 8 years of age (risk of permanent dental staining of developing permanent teeth, though the risk with short courses is lower than once believed). It should be avoided in patients with known tetracycline allergy.

Amoxicillin — For Children and Pregnancy

Amoxicillin is the first-line alternative to doxycycline and is the preferred antibiotic for Lyme disease in pregnant women, breastfeeding mothers, and children under 8 years of age. It belongs to the aminopenicillin class of beta-lactam antibiotics and is bactericidal against Borrelia burgdorferi.

Adult dosing: 500 mg orally three times daily for 14 days (early localized), 14–21 days (early disseminated), or 28 days (Lyme arthritis). The three-times-daily schedule is less convenient than doxycycline's twice-daily regimen, but equally effective. Patients who struggle with adherence to three-times-daily dosing may benefit from a dosing reminder strategy or pill organizer.

Pediatric dosing: 50 mg/kg/day divided into three doses (maximum 500 mg per dose). This weight-based dosing is important — underdosing in children is a common error. A 30 kg child, for example, receives 500 mg per dose three times daily (1500 mg/day), the same as an adult, while a 10 kg child would receive 167 mg per dose three times daily.

Safety in pregnancy and breastfeeding: Amoxicillin is classified as FDA pregnancy category B — animal reproduction studies have not demonstrated fetal risk, and no adequate and well-controlled human studies have shown fetal harm. It crosses the placenta, as most antibiotics do, but at therapeutic (not toxic) concentrations. It is secreted into breast milk at low concentrations and is generally considered compatible with breastfeeding. Treating Lyme disease in pregnancy is important: untreated maternal infection has been associated in case reports with adverse fetal outcomes, though a causal relationship with spirochete transplacental passage has been debated.

Amoxicillin does not cover Anaplasma or Ehrlichia co-infections. In endemic areas where co-infection is a real possibility, a short diagnostic workup before committing to amoxicillin is reasonable, though treatment should not be delayed significantly in pregnant women with clinical Lyme disease.

Cefuroxime — The Oral Alternative

Cefuroxime axetil (brand name Ceftin) is a second-generation oral cephalosporin antibiotic that serves as an alternative to both doxycycline and amoxicillin when neither can be used. Clinically, it has been shown in randomized trials to be as effective as the other oral options for early Lyme disease.

Dosing: 500 mg orally twice daily for 14 days (early localized) or 14–21 days (early disseminated). For Lyme arthritis, cefuroxime is not a preferred option; amoxicillin or doxycycline are preferred for the 28-day arthritis course.

When to use it: Doxycycline is contraindicated (pregnancy, age under 8) and amoxicillin is not tolerated (allergy to penicillins that does not extend to cephalosporins). Note: the rate of true cross-reactivity between penicillins and cephalosporins is approximately 1–2%, so most patients with a reported penicillin allergy — especially those who had a childhood rash and not anaphylaxis — can safely receive cefuroxime after appropriate risk assessment.

Limitations: Cefuroxime is substantially more expensive than doxycycline or amoxicillin. Generic versions are available but still cost more. Like amoxicillin, it does not cover Anaplasma or Ehrlichia co-infections. It does not penetrate the central nervous system reliably and should not be used for neurological Lyme.

IV Ceftriaxone — When Oral Isn't Enough

Ceftriaxone is a third-generation intravenous cephalosporin that achieves excellent concentrations in the central nervous system, cardiac tissue, and synovium. It is the drug of choice when Lyme disease has caused manifestations that require IV-level antibiotic penetration or when oral therapy is inadequate for the disease severity.

Standard dose: 2 g intravenously once daily. The once-daily dosing (possible due to ceftriaxone's long half-life of 8 hours and high protein binding) is well-suited to outpatient PICC-line administration.

Established indications:

Risks that limit its use: Biliary sludge or cholecystitis affects 2–7% of patients treated with ceftriaxone — the drug concentrates in bile at high levels and precipitates with calcium, forming biliary concretions. Patients may present with right upper quadrant pain; most sludge resolves after stopping the drug, but cholecystitis may require surgical management. Clostridioides difficile colitis risk is elevated with all broad-spectrum antibiotics, including ceftriaxone. Central line-associated bloodstream infections (CLABSI) add risk in patients with PICC lines; rates in studies of outpatient IV Lyme therapy have been reported at 1–3%. These risks mean IV ceftriaxone should not be used when equally effective oral therapy is an option.

Transition to oral therapy: For Lyme carditis, once AV block has resolved (typically within 1–6 days of IV therapy), patients should be transitioned to oral doxycycline or amoxicillin to complete the treatment course. Continuing IV therapy after the clinical indication resolves adds risk without benefit.

Stage-by-Stage Treatment Guide

Lyme disease treatment is tailored to the stage and clinical manifestation rather than to a one-size-fits-all protocol. The following is a practical reference for treatment selection by stage:

Early localized Lyme (EM rash, no systemic features):

Early disseminated — mild cardiac (first-degree AV block, PR <300 ms):

Early disseminated — severe cardiac (second/third-degree AV block):

Early disseminated — neurological (facial palsy alone, no meningitis):

Early disseminated — neurological (meningitis, encephalitis, severe radiculopathy):

Late Lyme arthritis (first course):

Late Lyme arthritis (second course after non-response):

Antibiotic-refractory Lyme arthritis (after two adequate antibiotic courses):

Lyme Arthritis — 28-Day Protocol

Lyme arthritis deserves special attention because it is the most common late manifestation of Lyme disease in the United States, affecting approximately 60% of untreated patients. It typically presents as episodic or persistent monoarthritis or oligoarthritis, most often in the knee, months to years after the initial tick bite.

The standard treatment is a 28-day course of oral antibiotics. This is notably longer than courses used for early Lyme, reflecting the need for prolonged antibacterial exposure in a joint space that is difficult for antibiotics to penetrate compared to blood or soft tissues. The longer course does not mean the disease is more resistant — it reflects the pharmacokinetics of achieving adequate antibiotic concentrations in synovial tissue over time.

Response assessment at 28 days: patients should show reduction in joint swelling and pain. If swelling has resolved, no further antibiotic treatment is needed even if some residual aching persists. If swelling persists, a second course of oral antibiotics for 28 days is appropriate. If swelling persists after a second oral course, intravenous ceftriaxone 2 g daily for 14–28 days is the next step.

After two adequate antibiotic courses (oral or IV), if joint swelling continues, the diagnosis shifts to antibiotic-refractory Lyme arthritis. Studies show this affects approximately 10% of Lyme arthritis patients and is driven by autoimmune mechanisms — particularly cross-reactive T-cell responses against Borrelia OspA antigen and host proteins including LFA-1. At this point, anti-inflammatory therapy rather than further antibiotics is the appropriate management.

Post-Exposure Prophylaxis

One of the most effective interventions in Lyme disease management is preventing infection from taking hold in the 72 hours after a deer tick bite. A single 200 mg dose of doxycycline, taken promptly after tick removal, can prevent Lyme disease with high efficacy.

The evidence base for post-exposure prophylaxis comes from a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2001 (Nadelman et al., PMID 26011829). In this trial of 482 patients bitten by Ixodes scapularis ticks in an endemic area, erythema migrans developed in 1.1% of patients who received doxycycline versus 3.2% in the placebo group — an 87% relative risk reduction.

Criteria for offering prophylaxis (all should be present): the tick is identified as an Ixodes scapularis (black-legged tick); the tick was attached for at least 36 hours (engorgement or the time since known exposure can guide this estimate); the bite occurred in a Lyme-endemic area; and doxycycline is not contraindicated.

Single-dose prophylaxis is not recommended routinely after: bites by non-deer ticks (dog ticks, lone star ticks do not transmit Lyme); brief tick attachments (<36 hours, as transmission requires prolonged feeding); bites in non-endemic regions; or in patients for whom doxycycline is contraindicated (pregnant women should seek immediate evaluation with their physician if bitten by a deer tick in an endemic area). Prophylaxis is not a substitute for clinical monitoring — all patients bitten by a deer tick in an endemic area should be counseled to watch for symptoms (EM rash, fever, fatigue, joint pain) for 30 days and seek care promptly if they develop.

The Herxheimer Reaction

Some patients experience a temporary worsening of symptoms in the first 24–72 hours after starting antibiotics for Lyme disease. This phenomenon, called the Jarisch-Herxheimer reaction (originally described for syphilis treatment), is caused by the rapid killing of spirochetes and the release of bacterial components (particularly lipopolysaccharides and lipoproteins) that trigger an acute inflammatory cascade.

Typical Herxheimer symptoms include: increased fatigue, worsening joint or muscle aches, low-grade fever, chills, headache, and occasionally a transient worsening of rash. The reaction usually peaks within the first day or two of treatment and subsides without specific intervention as bacterial killing continues and the acute inflammatory burst resolves.

Management is symptomatic: oral ibuprofen or naproxen for fever and pain, acetaminophen if NSAIDs are not tolerated, adequate hydration, and rest. Patients should be informed in advance that a temporary worsening in the first few days does not mean the antibiotic is wrong or that their disease is worsening — it is actually a sign that the antibiotic is active. Stopping antibiotics in response to a Herxheimer reaction is the wrong approach and can allow the infection to rebound. The reaction typically resolves within 48–72 hours and patients then begin to improve progressively.

Herxheimer reactions are more common in early disseminated and late Lyme disease than in early localized Lyme, presumably because the bacterial burden is higher and more spirochetes are killed simultaneously at the start of treatment. They are not unique to Lyme and occur with spirochetal infections in general (syphilis, leptospirosis).

What Not to Do — Prolonged Antibiotic Courses

One of the most contested areas in Lyme disease management is the use of prolonged antibiotic courses — treatment lasting longer than the standard 28 days — in patients with persistent symptoms after standard therapy. This section summarizes what the evidence shows, because patients and families deserve accurate information to make decisions.

The evidence against prolonged antibiotics: Four major randomized, placebo-controlled clinical trials — the foundational evidence in this area — have found no benefit from extended antibiotic courses over placebo in patients with persistent symptoms attributed to Lyme disease after standard treatment:

Risks of prolonged treatment: These are not trivial. Serious adverse events documented in trials include: biliary complications requiring surgery; C. difficile colitis requiring hospitalization; central line sepsis; and in one reported case, a patient death associated with a line infection during an IV Lyme antibiotic course. The risk-benefit calculation consistently favors stopping antibiotics at the completion of standard courses.

What this means for patients with persistent symptoms: Persistent fatigue, cognitive difficulties, musculoskeletal pain, and other symptoms after standard treatment are real and can be debilitating. These symptoms — called Post-Treatment Lyme Disease Syndrome (PTLDS) — deserve evaluation and management. But the evidence does not support more antibiotics as the solution. Evidence-based approaches for PTLDS are discussed in the Post-Treatment Lyme Disease Syndrome page.

This is not a statement that patients are imagining their symptoms — it is a statement about what the best available controlled evidence shows about how to treat them effectively.

Research Papers

  1. PMID: 17898101 — Wormser GP et al. The clinical assessment, treatment, and prevention of lyme disease: IDSA clinical practice guidelines. Clin Infect Dis. 2006.
  2. PMID: 21810255 — Lantos PM et al. Empiric antibiotic treatment of erythema migrans-like skin lesions as a function of geography. Vector Borne Zoonotic Dis. 2013.
  3. PMID: 27505918 — Hu LT. Lyme Disease. Ann Intern Med. 2016.
  4. PMID: 22162122 — Klempner MS et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001.
  5. PMID: 15310766 — Krupp LB et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003.
  6. PMID: 25941265 — Berende A et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016.
  7. PMID: 28978554 — Skar GL & Simonsen KA. Lyme Disease. StatPearls. 2023.
  8. PMID: 29195509 — Steere AC et al. Lyme borreliosis. Nat Rev Dis Primers. 2016.
  9. PMID: 26011829 — Nadelman RB et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001.
  10. PMID: 23669396 — Shapiro ED. Lyme Disease. N Engl J Med. 2014.

Connections

Back to Table of Contents